and/or

12 News Items found

Science Byte

PSMA: A New Target for Prostate Cancer Treatment

Researchers have discovered how a high level of the protein PSMA in cells helps fuel prostate cancer.

Prostate cancer cells, colored red in scanning electron micrograph (SEM).

Feature

With MSK Leading the Way, Precision Medicine Links Lab Research to Patient Care

Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.

Announcement

Expanding the Impact of Precision Medicine to Fuel Discoveries

MSK’s Functional Genomics Initiative will enable basic scientists to take full advantage of the massive amount of data produced by tumor sequencing.

Christina Leslie and John Petrini

Finding

Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

(From left) MSK investigators Michael Berger, José Baselga, and Maurizio Scaltriti, and graduate student Pau Castel.

In the Lab

Molecular Studies Provide New Clues about Rare Soft Tissue Sarcoma

Genetic analysis reveals biomarkers and possible drug targets for malignant peripheral nerve sheath tumors.

Pictured: Ping Chi

In the Lab

Researchers Uncover Potential Target for “Undruggable” Form of Liver Cancer

In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer.

Pictured: Scott Lowe

Decoder

What Is Tumor Heterogeneity?

Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated.

Pictured: Gum ball machines

Announcement

Bold Initiative to Transform Cancer Care Established with a $100 Million Gift

With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.

Pictured: José Baselga, Agnès Viale,  Michael Berger & David Solit

In the Lab

Researchers Identify Mutations that Cause Some Breast Cancers to Resist Treatment

Memorial Sloan Kettering researchers have found genetic mutations that cause some breast cancers to develop resistance to hormone therapy.

Pictured: Sarat Chandarlapaty

Snapshot

New Technology Could Enable Immediate Detection of Tumor Borders during Surgery

Memorial Sloan Kettering scientists are developing new imaging instrumentation that could enable pathologist and surgeons to collaborate more seamlessly and reduce the need for repeat surgeries.

Breast cancer mosaic